VARIABILITY IN CHOLESTEROL CONTENT AND PHYSICAL-PROPERTIES OF LIPOPROTEINS CONTAINING APOLIPOPROTEIN B-100

被引:67
作者
ABATE, N
VEGA, GL
GRUNDY, SM
机构
[1] UNIV TEXAS, SW MED CTR, CTR HUMAN NUTR, DALLAS, TX 75235 USA
[2] UNIV TEXAS, SW MED CTR, DEPT CLIN NUTR, DALLAS, TX 75235 USA
[3] UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA
[4] UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA
[5] VET ADM MED CTR, DALLAS, TX 75216 USA
关键词
CHOLESTEROL; APOLIPOPROTEIN B-100; LDL; NONHDL; LDL PATTERNS;
D O I
10.1016/0021-9150(93)90187-Y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The primary objective of this study was to determine the variability in cholesterol carrying capacity of low density lipoproteins (LDLs) and other apolipoprotein B (ape B)-containing lipoproteins in normolipidemic men. One hundred and fifty-nine normolipidemic men, ages 21 to 73 years, were enrolled. In addition to determining plasma lipids and lipopropoteins, three primary measurements were made: ratios of cholesterol to apo B in LDL; the electrophoretic pattern of LDL, i.e. pattern A, AB, or B; and levels of cholesterol in all lipoproteins other than high density lipoproteins (nonHDL-cholesterol) along with total apo B. First, the data revealed that about 85%, of the variability of LDL-cholesterol levels can be accounted for by LDL-apo B levels, whereas the remaining 15% can be explained by differences in LDL-cholesterol/apo B ratios. Second, LDL electrophoretic pattern A was the predominant pattern in young adult men, but in older men the pattern shifted increasingly to AB and B. And third, there was a high correlation between nonHDL-cholesterol levels and total apo B levels, which suggests that nonHDL-cholesterol can be used as a relatively accurate surrogate for total apo B levels in normolipidemic individuals.
引用
收藏
页码:159 / 171
页数:13
相关论文
共 37 条
[1]  
ASSMANN G, 1983, CLIN CHEM, V29, P2026
[2]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
[3]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[4]  
AVOGARO P, 1979, LANCET, V1, P901
[5]   APOPROTEIN-B AND APOPROTEIN-A-1 AND CORONARY-ARTERY DISEASE IN HUMANS [J].
BRUNZELL, JD ;
SNIDERMAN, AD ;
ALBERS, JJ ;
KWITEROVICH, PO .
ARTERIOSCLEROSIS, 1984, 4 (02) :79-83
[6]   LOW-DENSITY-LIPOPROTEIN PARTICLE-SIZE AND CORONARY-ARTERY DISEASE [J].
CAMPOS, H ;
GENEST, JJ ;
BLIJLEVENS, E ;
MCNAMARA, JR ;
JENNER, JL ;
ORDOVAS, JM ;
WILSON, PWF ;
SCHAEFER, EJ .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (02) :187-195
[7]  
CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36
[8]   INFLUENCE OF OBESITY ON THE METABOLISM OF APOLIPOPROTEIN-B IN HUMANS [J].
EGUSA, G ;
BELTZ, WF ;
GRUNDY, SM ;
HOWARD, BV .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (02) :596-603
[9]   ABNORMALITIES IN VERY LOW, LOW, AND HIGH-DENSITY LIPOPROTEINS IN HYPERTRIGLYCERIDEMIA - REVERSAL TOWARD NORMAL WITH BEZAFIBRATE TREATMENT [J].
EISENBERG, S ;
GAVISH, D ;
OSCHRY, Y ;
FAINARU, M ;
DECKELBAUM, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (02) :470-482
[10]   HETEROGENEITY OF PLASMA LOW-DENSITY LIPOPROTEINS MANIFESTATIONS OF THE PHYSIOLOGIC PHENOMENON IN MAN [J].
FISHER, WR .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1983, 32 (03) :283-291